301301 Yili Chuanning Biotechnology
- 13.72
- +0.13+0.96%
Yili Chuanning Biotechnology News
Twining Biotech (301301.SZ): The company is currently full of orders
Gelonghui, May 31, 丨 Channing Biotech (301301.SZ) said on the investor interactive platform that the company is currently full of orders, production and operation conditions are all normal, and it is developing steadily.
Express News | Twining Biology: The company currently produces some synthetic biology products at the “synthetic biology production base”
Express News | 47 stocks were traded in large quantities, with Aier Ophthalmology leading the discount rate of 18.22%
Express News | Twining Biology: In the field of synthetic biology, existing products are bisabolol and 5-hydroxytryptophan
Twining Biotech (301301.SZ): No research on anti-aging drugs is currently being conducted
Gelonghui, May 17 丨 Chuan Ning Biology (301301.SZ) said on the investor interactive platform that the company is currently not conducting research on anti-aging drugs. In the field of biological fermentation, the company's main products include erythromycin thiocyanate intermediates, cephalosporin intermediates (7-ACA, 7-ADCA, D-7ACA), high-end cosmetic intermediates (6-APA, penicillin G potassium salt), crude ursodeoxycholic acid products, coenzyme Q10 mycelium, etc.; in the field of synthetic biology, the company focuses on health product ingredients, biopesticides, high-value added natural products, Raw materials and other sectors, Currently, there is bisabolol, 5
Twining Biology (301301.SZ): The synthetic biology project has now brought part of the company's revenue
Gelonghui, May 16, 丨 Chuan Ning Biotech (301301.SZ) said on the investor interactive platform that the company's synthetic biology project has brought some revenue to the company, but the current share of revenue is still relatively small. In the future, in the field of synthetic biology, the company will focus on health product raw materials, biological pesticides, high-value-added natural products, high-end cosmetic ingredients, etc., and the company will give full play to its existing advantages and continuously increase the contribution of synthetic biology products to the company's revenue.
Chuan Ning Biotech (301301.SZ): 2023 equity distribution, 10 distributions of 2.25 yuan, share registration date May 21
On May 15, Ge Longhui Biotech (301301.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 2.24,5595 (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 2,227,160,000 shares. The share registration date for this equity distribution is May 21, 2024, and the ex-dividend date is May 22, 2024.
Chuan Ning Biology (301301.SZ): Currently not cooperating with Jiangnan University
Gelonghui, May 14, 丨 Channing Biology (301301.SZ) said on the investor interactive platform that the company has not yet cooperated with Jiangnan University. The company has set up a research institute in Shanghai, and also has cooperative projects with various biological research institutes and well-known universities such as the Institute of Microbiology of the Chinese Academy of Sciences, the Tianjin Institute of Industrial Biotechnology, and East China University of Technology.
Twining Biology (301301.SZ): Currently, some synthetic biology products are produced at the “synthetic biology production base”
Gelonghui, May 14, 丨 Chuan Ning Biology (301301.SZ) said on the investor interactive platform that the company currently produces some synthetic biology products at the “synthetic biology production base”, such as bisabolol, 5-hydroxytryptophan, etc.; at the same time, some products have already entered the small test and pilot phase, such as: squalane, ergothione, inositol, ecdoine, etc.; currently, the Shanghai Research Institute continues to step up research and development efforts to actively promote the delivery of new synthetic biology products.
Express News | Twining Biotech: The company's daily business situation and internal and external production and operation environment have not changed significantly compared to before abnormal fluctuations
Dragon Tiger List丨Chuan Ning Biotech climbed more than 81% on the 5th, and today's net sales of 435 million yuan were on the list
Glonghui, May 8 | Chuan Ning Biotech (301301.SZ) rose 4.78% to a record high today, with a turnover of 3.133 billion yuan and a turnover rate of 29.55%; in the five trading days from April 29 to now, the stock has risen more than 81%. According to data from the Dragon Tiger List, Oriental Securities sold one seat, with a net sales of 233 million yuan; the Shanghai branch of Changjiang Securities sold three seats, with net sales of 129 million yuan; and Shenwan Hongyuan's Chengdu West First Ring Road Sales Department sold four seats, with net sales of 119 million yuan. Seats on the list bought 510 million yuan and sold 946 million yuan throughout the day, a total net
Twining Biotech traded a net sale of 603.495 million yuan today
Chuan Ning Biotech went up and down today, with a turnover of 2,136 billion yuan and a turnover rate of 22.56%. After the market, Dragon Tiger Index data showed that the Shenzhen Stock Connect exclusive seat bought 33.0815 million yuan and sold 56.1749 million yuan, with a net sale of 60.3495 million yuan.
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
The A-share synthetic biology concept continues to strengthen, and many stocks such as Blue Biotech rose and stopped
Gelonghui, May 6 | Azure Biotech has 4 consecutive boards, Channing Biotech, Lukang Pharmaceutical, and Boen Group have 2 consecutive boards. Guangji Pharmaceutical has risen and stopped, while Fuxiang Pharmaceutical, Fujilai, and Ekiduoli have advanced gains. According to the news, according to a report by the Wuxi Daily on the 4th, the synthetic biology innovation team at the Future Food Science Center of Jiangnan University used synthetic biology technology to produce hyaluronic acid of normal molecular weight using microbial fermentation, reducing the cost from tens of thousands of yuan per kilogram to several hundred yuan per kilogram, and achieving large-scale production promotion and application of hyaluronic acid. Furthermore, since last year, Beijing, Jiangsu, Shanghai and other places have successively introduced policies to support the development of the biological manufacturing industry.
The concept of synthetic biology is highly open, and Twining Biotech is more than 10%
The concept of synthetic biology was highly open. Twining Biotech went up and down in bids for Boen Group and Blue Biotech, and Lukang Pharmaceuticals, Fujilai, etc.
Express News | Twining Biotech: There have been no major changes in the company's daily business conditions or internal and external production and operation environment
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
The chemical pharmaceutical concept fluctuated and boosted the rise and fall of Twining Biotech
The chemical pharmaceutical concept fluctuated and picked up. Twining Biotech and Hypry both went up and down, while Alex, Tonghe Pharmaceuticals, Osecon, and Borui Pharmaceuticals followed suit.
Express News | The synthetic biology concept continues to be strong, and Twining Biotech surged 15%
Dongwu Securities released a research report on April 28 stating that it gave Channing Biotech (301301.SZ) a purchase rating. The main reasons for the rating include: 1) performance is accelerating quarterly, and I am optimistic that the company's profita
Dongwu Securities released a research report on April 28 stating that it gave Channing Biotech (301301.SZ) a purchase rating. The main reasons for the rating include: 1) performance is accelerating quarterly, and I am optimistic that the company's profitability will be restored; 2) the synthetic biology R&D pipeline is rich, production capacity is abundant, and the project is about to be implemented. (Mainichi Keizai Shimbun)
Analysis
Price Target
No Data
